升荣胶囊联合化疗治疗晚期大肠癌疗效观察

Clinical study on advanced colorectal cancer treated by shengrong capsule combined with chemotherapy

目的:观察升荣胶囊联合草酸铂+CF+5-FU治疗晚期大肠癌的疗效。方法:64例晚期大肠癌患者,分为治疗组(34例,升荣胶囊联合化疗)和对照组(30例,单纯化疗)观察两组疗效。结果:治疗组和对照组的临床受益率(CR+PR+SD)分别为88.2%和60.0%(P<0.05),9个月及12个月生存率分别为81.5%,74.6%和67.3%,45.8%(P<0.05)。升荣胶囊可提高细胞及体液免疫功能、杀伤肿瘤细胞,降低患者的血液高凝状态、缓解化疗药物的不良反应、改善患者的生活质量。结论:升荣胶囊联合草酸铂+CF+5-FU治疗晚期大肠癌有较好的疗效。

Objective：To observe the effect of Shengrong capsule combined with L-OHP＋CF＋5-FU regimen in treating advanced colorectal cancer patients.Methods：Sixty four advanced colorectal cancer patients were randomly assigned to treatment group（34 patients,treated by Shengrong capsule combined with L-OHP ＋CF ＋5-FU） and control group（30 patients,treated with L-OHP ＋ CF＋5-FU regimen）.The therapeutic effects of two groups were observed.Results：Clinical beneficial rates（CR＋PR＋SD） of treatment group and control group were 88.2% and 60.0% respectively（P〈0.05）,9 and 12 month survival rates were 81.5%,74.6% and 67.3%,45.8%（P〈0.05）.Shengrong capsule decreased blood hypercoagulability,improved cellular immune function of patients,relieved myelosuppression of chemotherapeutic agents and improved quality of life of patients.Conclusion：Shengrong capsule combined with L-OHP ＋CF＋5-FU regimen had better effect in treatment of advanced colorectal cancer patients.